A series of new piperidyl-4-ethane derivatives possessing antiarrhythmic activity has been synthesized and studied. The most active compound, hydrochloride 1-(4-fluorophenyl)-1-(4-nitrobenzoylamino)-2-(N-ethyl-4-piperidyl)-ethane (niferidyl), was selected for clinical trials as a potential class III antiarrhythmic drug.
原文链接
分享
引用
